TTF1 status as a better predictor of benefit to erlotinib (E) in metastatic non-small cell lung cancer (NSCLC) than sex, histology, and smoking status.

e19110 Background: Erlotinib (E) is currently indicated as first line therapy in patients with EGFR mutations, and as second and third line treatment for patients with advanced metastatic NSCLC. In Cyprus comprehensive EGFR testing started in January 2011. In this study we reviewed all the patients that received E between 2007-2010, without having undergone EGFR mutation testing, looking at predictive factors for benefit. Methods: 100 consecutive patients are included. 3 patients received this as 1st line, 49 patiens as 2nd line and 48 patients as 3rd line and beyond. Previous treatments gemcitabine platinum doublet as first line, and either pemetrexed or docetaxel as 2nd line therapy. Patients had regular Chest x-rays (every 2-3 months) and CT scans (every 4-6 months). Results: 40 female and 60 male, with 9 patients still alive and on treatment. Median age is 66 years (range 32-79). 45 patients were WHO performance status (PS) 0-1, 47 PS 2-3, 8 patients PS not recorded. Median progression-free survival (...